drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Bispecific T-cell engager (CD3xCD19) immunotherapy that redirects patient T cells to kill CD19-positive leukemic B cells; used here for MRD-positive B-ALL.
nci_thesaurus_concept_id
C62528
nci_thesaurus_preferred_term
Blinatumomab
nci_thesaurus_definition
A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.
drug_mesh_term
blinatumomab
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Blinatumomab is a CD3×CD19 bispecific T‑cell engager that links patient T cells (via CD3) to CD19‑positive B cells, inducing MHC‑independent T‑cell activation and immune synapse formation, resulting in perforin/granzyme‑mediated cytotoxicity and serial killing of CD19+ leukemic cells.
drug_name
blinatumomab
nct_id_drug_ref
NCT06237192